Recruiting Spinal Muscular Atrophy Studies in Palo Alto
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a ...
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread fr...
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3...
Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer
This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The ...
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered in pediatric participants with SMA and 2 SMN2 copies who previously rec...
About Spinal Muscular Atrophy Clinical Trials in Palo Alto
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.
There are currently 5 spinal muscular atrophy clinical trials recruiting participants in Palo Alto, CA. These studies are seeking a combined 286 participants. Research is being sponsored by SWOG Cancer Research Network, NMD Pharma A/S, CellSight Technologies, Inc. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Spinal Muscular Atrophy Clinical Trials in Palo Alto — FAQ
Are there spinal muscular atrophy clinical trials in Palo Alto?
Yes, there are 5 spinal muscular atrophy clinical trials currently recruiting in Palo Alto, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Palo Alto?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.
Are clinical trials in Palo Alto free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.
What spinal muscular atrophy treatments are being tested?
The 5 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.
Data updated March 2, 2026 from ClinicalTrials.gov